SPRB (Spruce Biosciences) Risk Assessment


SPRB Spruce Biosciences Inc SPRB
40 GF Score
Price $51.85
GF Value $4.08
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Spruce Biosciences Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Spruce Biosciences is: No Data: Cannot be evaluated.

Spruce Biosciences  (NAS:SPRB) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Spruce Biosciences Risk Assessment Related Terms

SPRB vs TLSA, MIST, TNYA: Risk Assessment Comparison

For the Biotechnology subindustry, Spruce Biosciences's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spruce Biosciences Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spruce Biosciences's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Spruce Biosciences's Risk Assessment falls into.


SPRB
40GF Score
Spruce Biosciences Inc SPRB
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Spruce Biosciences (SPRB) Overvalued in 2026?

Based on GuruFocus' analysis, Spruce Biosciences stock appears to be overvalued. The current stock price of $51.85 is trading 1170.8% above its estimated GF Value™ of $4.08. GuruFocus considers Spruce Biosciences to be Significantly Overvalued.

Key valuation signals for SPRB:

  • Risk Assessment:
  • GF Value™: $4.08 vs. price of $51.85 (1170.8% above fair value)
  • GF Score™: 40/100 with 1 warning sign

No single metric tells the full story. See the SPRB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spruce Biosciences Business Description

Address 611 Gateway Boulevard, Suite 740, South San Francisco, CA, USA, 94080
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
40GF Score

Get the complete analysis for SPRB

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$51.85
Price
$4.08
GF Value